Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab (DrugBank: Adalimumab, Infliximab, Ustekinumab, Golimumab, Vedolizumab)
25 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
35 | Pemphigus | 0 |
37 | Generalised pustular psoriasis | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
55 | Relapsing polychondritis | 0 |
56 | Behcet disease | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 1 |
98 | Eosinophilic gastrointestinal disease | 0 |
162 | Pemphigoid | 0 |
164 | Oculocutaneous albinism | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03885713 (ClinicalTrials.gov) | September 10, 2019 | 4/3/2019 | Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease | Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches | Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis | Biological: Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | NULL | Recruiting | 18 Years | N/A | All | 180 | Phase 4 | Spain |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03885713 (ClinicalTrials.gov) | September 10, 2019 | 4/3/2019 | Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease | Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches | Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis | Biological: Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | NULL | Recruiting | 18 Years | N/A | All | 180 | Phase 4 | Spain |